Skip to main content
Clinical Trials/NCT02536378
NCT02536378
Completed
Not Applicable

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE. The ROADSTER 2 Study.

Silk Road Medical43 sites in 3 countries692 target enrollmentStarted: October 23, 2015Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
692
Locations
43
Primary Endpoint
Number of Participants With Procedural Success

Overview

Brief Summary

The ROADSTER 2 Study is intended to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System by physicians of varying experience with the transcarotid technique.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • A. Contralateral carotid artery occlusion B. Tandem stenoses \>70% C. High cervical carotid artery stenosis D. Restenosis after carotid endarterectomy E. Bilateral carotid artery stenosis requiring treatment within 30 days after index treatment.
  • F. Hostile Necks which the Investigator deems safe for transcarotid access including but not limited to:
  • I. Prior neck irradiation II. Radical neck dissection III. Cervical spine immobility
  • Clinical High Risk Inclusion Criteria:
  • G. Patient is \> 75 years of age H. Patient has \> 2-vessel coronary artery disease and history of angina of any severity I. Patient has a history of angina
  • Canadian Cardiovascular Society (CCS) angina class 3 or 4 or
  • unstable angina
  • J. Patient has congestive heart failure (CHF) - New York Heart Association (NYHA)
  • Functional Class III or IV
  • K. Patient has known severe left ventricular dysfunction

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of Participants With Procedural Success

Time Frame: 30 Days

Procedural success is defined as acute device success (successful insertion of the ENROUTE NPS and establishment of flow reversal), technical success (deployment of interventional tools) and the absence of a major adverse events (hierarchical stroke/death/myocardial infarction) through 30 days.

Secondary Outcomes

  • Number of Participants Experiencing Major Adverse Event(30 days)
  • Number of Participants With Acute Device Success(2 hours (periprocedural))
  • Number of Participants With Technical Success(2 hours (periprocedural))
  • Number of Participants in Which a Cranial Nerve Injury Occurred(90 days (extended follow-up))

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (43)

Loading locations...

Similar Trials